title: When to screen and not to screen.
abstract: Colorectal cancer (CRC) is the third most common cause of cancer-related deaths with treatment of advanced and metastatic CRC (mCRC) remaining palliative at best. (1) The epidermal growth factor receptor (EGFR) has been identified as a therapeutic target for a multitude of malignancies, including mCRC. Ligand-binding to EGFR results in the subsequent activation of multiple signal transduction pathways including the PI3K/AKT and RAS/RAF/MAPK pathways, which are vital for cell growth and survival. (2) Constitutive activation of these signaling pathways leads to deregulated cellular proliferation, malignant progression, and invasion. (3.)
authors.affiliation: Department of Biochemistry; Virginia Commonwealth University; Richmond, VA USA.
authors.forename: Nichola
authors.initials: N
authors.lastname: Cruickshanks
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D018631:ras Proteins / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D018631:ras Proteins
keywords: EGFR; cetuximab; colon carcinoma; monoclonal antibodies; panitumumab; resistance